SAN FRANCISCO and GENEVA, Dec. 29, 2014 (GLOBE NEW

SAN FRANCISCO and GENEVA, Dec. 29, 2014 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics in Alzheimer's disease and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced it will be presenting a corporate overview including top-line results of its expanded LP-002 study of the Lymphocyte Proliferation Test (LymPro Test®) blood diagnostic for Alzheimer's disease (AD) at Biotech Showcase 2015. Gerald E. Commissiong, President & CEO of Amarantus, will present on Wednesday, January 14, 2015 at the Parc 55 Wyndham Union Square in San Francisco, CA.

http://ir.amarantus.com/company-news/detail/1...ry-14-2015